

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 May 2006 (04.05.2006)

PCT

(10) International Publication Number
WO 2006/047479 A2

(51) International Patent Classification: Not classified

Plainsboro, NJ 08536 (US). **GEORGIADIS, Taxiarchis**
[US/US]; 12369 Bayhill Drive, Carmel, IN 46033 (US).

(21) International Application Number:
PCT/US2005/038307

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 20 October 2005 (20.10.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/970,865 22 October 2004 (22.10.2004) US

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA, N.V. [BE/BE];
Turnhoutseweg 30, B-2340 Beerse (BE).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **PLAYER, Mark, R.** [US/US]; 5022 Swan Drive, Phoenixville, PA 19460 (US). **BAINDUR, Nand** [IN/US]; 7 Jared Boulevard, Kendall Park, NJ 08824 (US). **BRANDT, Benjamin, M.** [US/US]; 6704 Cresheim Rd., Philadelphia, PA 19119 (US). **CHADHA, Naresh** [US/US]; 3 Timber Road, Montville, NJ 07045 (US). **PATCH, Raymond, J.** [US/US]; 157 Pinnacle Circle, Yardley, PA 19067 (US). **ASGARI, Davoud** [IR/US]; 1208 Quail Ridge Drive,

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: C-FMS KINASE INHIBITORS



(1)

(57) Abstract: The invention is directed to compounds of Formula (I) wherein A, R₁, R₂, R₃, R₄, X, and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

United States Patent Application

Of

Mark R. Player,

Raymond J. Patch,

Benjamin M. Brandt,

Nand Baindur,

Davoud Asgari,

Naresh Chadha

and

Taxiarchis Georgiadis

for

c-fms Kinase Inhibitors

Title: c-fms Kinase Inhibitors

Inventors: Mark R. Player, Nand Baindur, Benjamin M. Brandt, Naresh Chadha, Raymond J. Patch, Davoud Asgari, and Taxiarchis Georgiadis

Relationship to Other Applications and Priority Claim: This application is a continuation-in-part of USSN 10/831,216, filed April 26, 2004, now _____; which in turn claimed benefit under 35 U.S.C. § 119(e) to Provisional Application No. 60/465,204, filed April 25, 2003.

FIELD OF THE INVENTION

[0001] The invention relates to novel compounds that function as protein tyrosine kinase inhibitors. More particularly, the invention relates to novel compounds that function as inhibitors of c-fms kinase.

BACKGROUND OF THE INVENTION

[0002] Protein kinases are enzymes that serve as key components of signal transduction pathways by catalyzing the transfer of the terminal phosphate from ATP to the hydroxy group of tyrosine, serine and threonine residues of proteins. As a consequence, protein kinase inhibitors and substrates are valuable tools for assessing the physiological consequences of protein kinase activation. The overexpression or inappropriate expression of normal or mutant protein kinases in mammals has been demonstrated to play significant roles in the development of many diseases, including cancer and diabetes.

[0003] Protein kinases can be divided into two classes: those which preferentially phosphorylate tyrosine residues (protein tyrosine kinases) and those which preferentially phosphorylate serine and/or threonine residues (protein serine/threonine kinases). Protein tyrosine kinases perform diverse functions ranging from stimulation of cell growth and differentiation to arrest of cell proliferation. They can be classified as either receptor protein tyrosine kinases or intracellular protein tyrosine kinases. The receptor protein tyrosine kinases, which possess an extracellular

ligand binding domain and an intracellular catalytic domain with intrinsic tyrosine kinase activity, are distributed among 20 subfamilies.

[0004] Receptor tyrosine kinases of the epidermal growth factor ("EGF") family, which includes HER-1, HER-2/neu and HER-3 receptors, contain an extracellular binding domain, a transmembrane domain and an intracellular cytoplasmic catalytic domain. Receptor binding leads to the initiation of multiple intracellular tyrosine kinase dependent phosphorylation processes, which ultimately results in oncogene transcription. Breast, colorectal and prostate cancers have been linked to this family of receptors.

[0005] Insulin receptor ("IR") and insulin-like growth factor I receptor ("IGF-1R") are structurally and functionally related but exert distinct biological effects. IGF-1R over-expression has been associated with breast cancer.

[0006] Platelet derived growth factor ("PDGF") receptors mediate cellular responses that include proliferation, migration and survival and include PDGFR, the stem cell factor receptor (c-kit) and c-fms. These receptors have been linked to diseases such as atherosclerosis, fibrosis and proliferative vitreoretinopathy.

[0007] Fibroblast growth factor ("FGR") receptors consist of four receptors which are responsible for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.

[0008] Vascular endothelial growth factor ("VEGF"), a potent mitogen of endothelial cells, is produced in elevated amounts by many tumors, including ovarian carcinomas. The known receptors for VEGF are designated as VEGFR-1 (Flt-1), VEGFR-2 (KDR), VEGFR-3 (Flt-4). A related group of receptors, tie-1 and tie-2 kinases, have been identified in vascular endothelium and hematopoietic cells. VEGF receptors have been linked to vasculogenesis and angiogenesis.


[0009] Intracellular protein tyrosine kinases are also known as non-receptor protein tyrosine kinases. Over 24 such kinases have been identified and have been classified into 11 subfamilies.

The serine/threonine protein kinases, like the cellular protein tyrosine kinases, are predominantly intracellular.

[0010] Diabetes, angiogenesis, psoriasis, restenosis, ocular diseases, schizophrenia, rheumatoid arthritis, cardiovascular disease and cancer are exemplary of pathogenic conditions that have been linked with abnormal protein tyrosine kinase activity. Thus, a need exists for selective and potent small-molecule protein tyrosine kinase inhibitors. U.S. Patent Nos. 6,383,790; 6,346,625; 6,235,746; 6,100,254 and PCT International Applications WO 01/47897, WO 00/27820 and WO 02/068406 are indicative of recent attempts to synthesize such inhibitors.

SUMMARY OF THE INVENTION

[0011] The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. One embodiment of the invention is directed to the novel compounds of Formula I:



or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein

A is

phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -COR_a, -CN, -C(NH)NH₂, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b; or

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with one or more of -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl,

guanidinoalkyl, heteroaryl, halogen, hydroxy, $-CF_3$, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, $-OCF_3$, $-OCO$ -alkyl, $-COR_a$, $-CN$, $-C(NH)NH_2$, $-COOR_a$, $-CONR_aR_b$, $-N(R_a)COR_b$, $-NO_2$, $-SO_2R_a$, $-SO_3R_a$ or $-SO_2NR_aR_b$;

R_1 is

$-H$, aryl, $-COR_a$, $-COR_a$, $-COOR_a$, $-CONR_aR_b$, $-SO_2R_a$ or $-SO_2NR_aR_b$;

X is

$-CO-$, $-C(=NH)-$, $-CS-$, $-CON(R_a)-$, $-CS(NR_a)-$, $-SO_2-$ or $-CR_aR_b-$;

R_2 and R_3 are independently

$-H$, $-C_{1-6}$ alkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, $-COR_a$, $-COR_a$, $-COOR_a$, $-CONR_aR_b$, $-SO_2R_a$ or $-SO_2NR_aR_b$; or

R_2 and R_3 , taken together with the attached nitrogen, form

a 5- to 7-membered heterocyclic or heteroaromatic ring containing from one to three heteroatoms selected from N, O or S, which may be optionally substituted with $-C_{1-6}$ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, $-CF_3$, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, $-OCF_3$, $-OCO$ -alkyl, $-OCO$ -alkylamino, $-OCO$ -alkylamido, $-COR_a$, $-CN$, $-COOR_a$, $-CONR_aR_b$, $-N(R_a)COR_b$, $-NO_2$, $-SO_2R_a$, $-SO_3R_a$ or $-SO_2NR_aR_b$; and

W is

phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C_{1-4} alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, halogen, hydroxy, $-CF_3$, alkoxy, aryloxy, arylalkoxy, $-OCF_3$, $-COR_a$, $-CN$, $-C(NH)NH_2$, $-COOR_a$, $-CONR_aR_b$, $-NHCOR_aR_b$, $-NHCO_2R_a$, $-NO_2$, $-SOR_a$, $-SO_3R_a$ or $-SO_2NR_aR_b$; or

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heterocyclic or heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with $-C_{1-6}$ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, $-CF_3$, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, $-OCF_3$,

-OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, -COR_a, -CN, -C(NH)NH₂, -COOR_a,
 -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b,


wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

[0012] The compounds of Formulae I and II are especially potent inhibitors of the c-fms protein tyrosine kinase. The compounds of Formula III are expected to exhibit similar inhibitory potencies.

[0013] The invention also relates to methods of inhibiting protein tyrosine kinase activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I, II or III.

DETAILED DESCRIPTION OF THE INVENTION

[0014] The invention is directed to the novel compounds of Formula I:



or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein

A is

phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -COR_a, -CN, -C(NH)NH₂, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b; or

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with one or more of -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -COR_a, -CN, -C(NH)NH₂, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b;

R₁ is

-H, aryl, -COR_a, -COR_a, -COOR_a, -CONR_aR_b, -SO₂R_a or -SO₂NR_aR_b;

X is

-CO-, -C(=NH)-, -CS-, -CON(R_a)-, -CS(NR_a)-, -SO₂- or -CR_aR_b-;

R₂ and R₃ are independently

-H, -C₁₋₆ alkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, -COR_a, -COR_a, -COOR_a, -CONR_aR_b, -SO₂R_a or -SO₂NR_aR_b; or

R₂ and R₃, taken together with the attached nitrogen, form

a 5- to 7-membered heterocyclic or heteroaromatic ring containing from one to three heteroatoms selected from N, O or S, which may be optionally substituted with -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, -COR_a, -CN, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b; and

W is

phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C₁₋₄ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, halogen, hydroxy, -CF₃, alkoxy, aryloxy, arylalkoxy, -OCF₃, -COR_a, -CN, -C(NH)NH₂, -COOR_a, -CONR_aR_b, -NHCOR_aR_b, -NHCO₂R_a, -NO₂, -SOR_a, -SO₃R_a or -SO₂NR_aR_b; or

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heterocyclic or heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally

substituted with -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, -COR_a, -CN, -C(NH)NH₂, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b,

wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

[0015] Preferred compounds of Formula I are those wherein

A is phenyl;

R₁ is -H; and

R₂ and R₃, taken together with the attached nitrogen, form a piperidine, piperazine, morpholine, thiomorpholine, pyrrolidine, pyrroline, pyrazolidine, pyrazoline, imidazolidine or imidazoline ring which may be optionally substituted with -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, -COR_a, -CN, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b,

wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

[0016] Particularly preferred compounds of Formula I are those wherein

A is phenyl;

R₁ is -H;

R₂ and R₃, taken together with the attached nitrogen, form a piperidine, piperazine, morpholine, thiomorpholine, pyrrolidine, pyrroline, pyrazolidine, pyrazoline, imidazolidine or imidazoline ring which may be optionally substituted with -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, -COR_a, -CN, -C(NH)NH₂, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b; and

W is a phenyl, furan, thiophene, isoxazole, pyrrole, oxazole, thiazole, imidazole, pyrazole, isothiazole, triazole, pyridine, pyridazine, pyrimidine, pyrazine or triazine ring which may be optionally substituted with -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, -COR_a, -CN, -C(NH)NH₂, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b,

wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

The most preferred compounds of Formula I include, but are not limited to, 5-cyano-furan-2-carboxylic acid [2-(4-acetylamino-piperidin-1-yl)-phenyl]-amide, 5-cyano-1H-pyrrole-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide, 5-cyano-furan-2-carboxylic acid (4-methoxy-2-piperidin-1-yl-phenyl)-amide, 5-cyano-furan-2-carboxylic acid (4-imidazol-1-yl-2-piperidin-1-yl-phenyl)-amide, 5-cyano-furan-2-carboxylic acid (4-dimethylamino-2-piperidin-1-yl-phenyl)-amide, 5-cyano-furan-2-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-phenyl]-amide, 5-cyano-furan-2-carboxylic acid (4-ethoxy-2-piperidin-1-yl-phenyl)-amide, 5-cyano-furan-2-carboxylic acid (3-chloro-2-piperidin-1-yl-phenyl)-amide, 5-cyano-furan-2-carboxylic acid (3-methyl-2-piperidin-1-yl-phenyl)-amide, 5-cyano-furan-2-carboxylic acid (2-piperidin-1-yl-4-pyrazol-1-yl-phenyl)-amide, 5-cyano-furan-2-carboxylic acid [4-(acetyl-methyl-amino)-2-piperidin-1-yl-phenyl]-amide, 5-cyano-furan-2-carboxylic acid (4-acetylamino-2-piperidin-1-yl-phenyl)-amide, 5-cyano-furan-2-carboxylic acid [2-(4-methyl-piperidin-1-yl)-4-pyridin-4-yl-phenyl]-amide bis(trifluoroacetic acid salt), 3H-imidazole-4-carboxylic acid (2-piperidin-1-yl-phenyl)-amide bis(trifluoroacetic acid salt), or 5-cyano-1H-imidazole-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide trifluoroacetic acid salt, and pharmaceutically acceptable salts thereof.

[0017] The invention also relates to methods of inhibiting protein tyrosine kinase activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula. A preferred tyrosine kinase is c-fms.

[0018] The invention is considered to include the enantiomeric, diastereomeric and tautomeric forms of all compounds of Formula I as well as their racemic mixtures. In addition, some of the compounds represented by Formulae I may be prodrugs, *i.e.*, derivatives of an acting drug that possess superior delivery capabilities and therapeutic value as compared to the acting drug. Prodrugs are transformed into active drugs by *in vivo* enzymatic or chemical processes.

1. Definitions

[0019] The term “alkyl” refers to both linear and branched chain radicals of up to 12 carbon atoms, unless otherwise indicated, and includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, heptyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl and dodecyl.

[0020] The term “cycloalkyl” refers to a saturated or partially unsaturated ring composed of from 3 to 8 carbon atoms. Alkyl substituents may optionally be present on the ring. Examples include cyclopropyl, 1,1-dimethyl cyclobutyl, 1,2,3-trimethylcyclopentyl, cyclohexyl and cyclohexenyl.

[0021] The term “heterocyclyl” refers to a nonaromatic (*i.e.* saturated or partially unsaturated) ring composed of from 3 to 7 carbon atoms and at least one heteroatom selected from N, O or S. Alkyl substituents may optionally be present on the ring. Examples include tetrahydrofuryl, dihydropyranyl, piperidyl, 2,5-dimethylpiperidyl, morpholinyl, piperazinyl, thiomorpholinyl, pyrrolidinyl, pyrrolinyl, pyrazolidinyl, pyrazolinyl, imidazolidinyl and imidazolinyl.

[0022] The term “heterocyclylalkyl” refers to a C₁₋₆ alkyl group containing a heterocyclyl substituent. Examples include dihydropyranylethyl and 2-morpholinylpropyl.

[0023] The term “hydroxyalkyl” refers to at least one hydroxyl group bonded to any carbon atom along an alkyl chain.

[0024] The term “aminoalkyl” refers to at least one primary or secondary amino group bonded to any carbon atom along an alkyl chain.

[0025] The term “alkoxyalkyl” refers to at least one alkoxy group bonded to any carbon atom along an alkyl chain.

[0026] The term “polyalkoxyalkyl” refers to long-chain alkoxy compounds and includes polyethylene glycols of discreet or monodispersed sizes.

[0027] The term “thioalkyl” refers to at least one sulfur group bonded to any carbon atom along an alkyl chain. The sulfur group may be at any oxidation state and includes sulfoxides, sulfones and sulfates.

[0028] The term “carboxyalkyl” refers to at least one carboxylate group bonded to any carbon atom along an alkyl chain. The term “carboxylate group” includes carboxylic acids and alkyl, cycloalkyl, aryl or aralkyl carboxylate esters.

[0029] The term “heteroaromatic” or “heteroaryl” refers to 5- to 7-membered mono- or 8- to 10-membered bicyclic aromatic ring systems, any ring of which may contain from one to four heteroatoms selected from N, O or S where the nitrogen and sulfur atoms can exist in any allowed oxidation state. Examples include benzimidazolyl, benzothiazolyl, benzothienyl, benzoxazolyl, furyl, imidazolyl, isothiazolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinoliny, thiazolyl and thienyl.

[0030] The term “heteroaralkyl” refers to a C₁₋₆ alkyl group having a heteroaryl substituent. Examples include furylethyl and 2-quinolinypropyl.

[0031] The term “heteroatom” refers to a nitrogen atom, an oxygen atom or a sulfur atom wherein the nitrogen and sulfur atoms can exist in any allowed oxidation states.

[0032] The term “alkoxy” refers to straight or branched chain radicals of up to 12 carbon atoms, unless otherwise indicated, bonded to an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy and butoxy.

[0033] The term "aryl" refers to monocyclic or bicyclic aromatic ring systems containing from 6 to 12 carbons in the ring. Alkyl substituents may optionally be present on the ring. Examples include benzene, biphenyl and naphthalene.

[0034] The term "aralkyl" refers to a C₁₋₆ alkyl group containing an aryl substituent. Examples include benzyl, phenylethyl or 2-naphthylmethyl.

[0035] The term "heteroaralkyl" refers to a C₁₋₆ alkyl group containing a heteroaryl substituent. Examples include furylmethyl and pyridylpropyl.

[0036] The term "aryloxy" refers to an oxygen atom bound to an aryl substituent. Examples include phenoxy and benzyloxy.

[0037] The term "arylalkoxy" refers to an alkoxy group bound to an aryl substituent. Examples include phenylmethyl ether.

[0038] The term "acyl" refers to the group -C(O)R_a, where R_a is alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl. An "acylating agent" adds the -C(O)R_a group to a molecule.

[0039] The term "sulfonyl" refers to the group -S(O)₂R_a, where R_a is hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl. A "sulfonylating agent" adds the -S(O)₂R_a group to a molecule.

II. Therapeutic Uses

[0040] The compounds of Formula I represent novel potent inhibitors of protein tyrosine kinases, such as c-fms, and may be useful in the prevention and treatment of disorders resulting from actions of these kinases.

[0041] The invention also provides methods of inhibiting a protein tyrosine kinase comprising contacting the protein tyrosine kinase with an effective inhibitory amount of at least one of the

compounds of Formula I. A preferred tyrosine kinase is c-fms. In one embodiment of inhibiting a protein tyrosine kinase, at least one of the compounds of Formula I is combined with a known tyrosine kinase inhibitor.

[0042] In various embodiments of the invention, the protein tyrosine kinases inhibited by the compounds of Formula I are located in cells, in a mammal or *in vitro*. In the case of mammals, which includes humans, a therapeutically effective amount of a pharmaceutically acceptable form of at least one of the compounds of Formula I is administered.

[0043] The invention further provides methods of treating cancer in mammals, including humans, by administration of a therapeutically effective amount of a pharmaceutically acceptable composition of least one compound of Formula I. Exemplary cancers include, but are not limited to, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma. In one embodiment of the invention, an effective amount of at least one compound of Formula I is administered in combination with an effective amount of a chemotherapeutic agent.

[0044] The invention also provides methods of treating cardiovascular and inflammatory diseases in mammals, including humans, by administration of a therapeutically effective amount of a pharmaceutically acceptable form of at least one of the compounds of Formula I. Examples of diseases that may be effectively treated include glomerulonephritis, rheumatoid arthritis, psoriasis, diabetes, tumor related angiogenesis, restenosis, schizophrenia and Alzheimer's dementia.

[0045] When employed as protein tyrosine kinase inhibitors, the compounds of the invention may be administered in an effective amount within the dosage range of about 0.5 mg to about 10 g, preferably between about 0.5 mg to about 5 g, in single or divided daily doses. The dosage administered will be affected by factors such as the route of administration, the health, weight and age of the recipient, the frequency of the treatment and the presence of concurrent and unrelated treatments.

[0046] The compounds of Formula I may be formulated into pharmaceutical compositions comprising any known pharmaceutically acceptable carriers. Exemplary carriers include, but are not limited to, any suitable solvents, dispersion media, coatings, antibacterial and antifungal agents and isotonic agents. Exemplary excipients that may also be components of the formulation include fillers, binders, disintegrating agents and lubricants.


[0047] The pharmaceutically-acceptable salts of the compounds of Formula I include the conventional non-toxic salts or the quaternary ammonium salts which are formed from inorganic or organic acids or bases. Examples of such acid addition salts include acetate, adipate, benzoate, benzenesulfonate, citrate, camphorate, dodecylsulfate, hydrochloride, hydrobromide, lactate, maleate, methanesulfonate, nitrate, oxalate, pivalate, propionate, succinate, sulfate and tartrate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts and salts with amino acids such as arginine. Also, the basic nitrogen-containing groups may be quaternized with, for example, alkyl halides.

[0048] The pharmaceutical compositions of the invention may be administered by any means that accomplish their intended purpose. Examples include administration by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal or ocular routes. Alternatively or concurrently, administration may be by the oral route. Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts, acidic solutions, alkaline solutions, dextrose-water solutions, isotonic carbohydrate solutions and cyclodextrin inclusion complexes.

III. Methods of Preparation

[0049] The compounds of Formula I may be prepared by either solid phase support methodology or by solution-phase synthesis. Exemplary synthetic routes for generating amides of the invention are described below.

Scheme 1



Scheme 1 illustrates general methodology for the preparation of compounds of Formula I.

[0051] Compounds of Formula 1-2 can be obtained by nucleophilic aromatic substitution on compounds of Formula 1-3 (where L₁ is a leaving group such as a halogen, preferably fluoro or chloro) with amines R₂R₃NH followed by reduction of the nitro group. Nucleophilic aromatic displacements can be performed in the presence of a suitable base such as excess R₂R₃NH, triethylamine (NEt₃) or K₂CO₃ in a suitable solvent such as dimethylformamide (DMF). Nitro reductions can be performed according to standard synthetic methodologies (for a review, see M. Hudlicky, *Reductions in Organic Chemistry*, Wiley, NY (1984)) and include preferred methods such as palladium-catalyzed hydrogenolysis or treatment with iron (0) and NH₄Cl (see, for example, S. Mitsumori, *et al*, *J. Med. Chem.*, 46: 2436-45 (2003)).

[0052] Alternatively compounds of Formula 1-2 can be obtained by ortho-halogenation (preferably bromination) of amino compounds of Formula 1-1 followed by metal-catalyzed aminations with R₂R₃NH. (For reviews, see: S. L. Buchwald, *et al*, *Top. Curr. Chem.*, 219:131-209 (2001) and J. F. Hartwig in "*Organopalladium Chemistry for Organic Synthesis*," Wiley Interscience, NY (2002) and examples therein.) Catalysts suitable for aminations include metal complexes and salts of palladium and copper as described below and in the aforementioned references. The NH₂ group may be optionally protected prior to the coupling using a number of protecting groups such as tert-butoxycarbonyl (BOC) (see, for example, M. C. Harris, *et al*, *Org. Lett.*, 4:2885-8 (2002).) (For examples of amine protecting groups and their use, see Theodora

W. Greene and Peter G. M. Wuts, John Wiley and Sons, Inc., NY (1991)). The preferred conditions for bromination are N-bromosuccinimide (NBS) in a suitable solvent such as *N,N*-dimethylformamide (DMF), dichloromethane (DCM) or acetonitrile. Metal-catalyzed aminations can be performed according to standard methodology, preferably in the presence of a palladium catalyst such as Pd₂(dba)₃ or Pd(OAc)₂, a ligand such as BINAP or preferably 2-diphenylphosphino-2'-(*N,N*-dimethylamino)biphenyl, a base such as Cs₂CO₃, and a suitable solvent such as toluene, dioxane or DME. The protecting group, if present, would then be removed at this point using suitable reagents, preferably trifluoroacetic acid in DCM if the protecting group was a BOC.

[0053] Compounds of Formula 1-4 can be prepared by reaction of compounds of Formula 1-2 with carboxylic acids WCOOH according to standard procedures for amide bond formation (for a review, see: M. Bodansky and A. Bodansky, *The Practice of Peptide Synthesis*, Springer-Verlag, NY (1984)) or by reaction with acid chlorides WCOCl or activated esters WCO₂Rq (where Rq is a leaving group such as pentafluorophenyl or N-succinimide). The preferred reaction conditions for coupling with WCOOH are: when W is a furan, oxalyl chloride in DCM with DMF as a catalyst to form the acid chloride WCOCl and then coupling in the presence of a trialkylamine such as *N,N*-diisopropylethylamine (DIEA); when W is a pyrrole, 1-(3-dimethylaminopropyl)-3-carbodiimide hydrochloride (EDCI) and 1-hydroxybenzotriazole (HOBt); and when W is an imidazole, the preferred conditions are bromotri(pyrrolidino)phosphonium hexafluorophosphate (PyBroP) and DIEA in DCM.

[0054] It is understood that the optional substitution present in Formula I may be present in the starting materials 1-1 or 1-3 and, in such cases, would be carried through the synthesis outlined in Scheme 1. Alternatively various substituents on compounds of Formula I may be introduced in a number of ways described below to provide the optional substitution listed for Formula I. For example, leaving groups present on compounds of Formula 1-1 or 1-3, can be substituted before or at any step during Scheme 1. When such leaving groups (preferably fluoro or chloro) are activated by the nitro group of Formula 1-3 for nucleophilic attack, they can undergo direct nucleophilic aromatic substitution by ammonia and azide anion or by amines, alcohols, thiols and other nucleophiles in the presence of a suitable base such as K₂CO₃, DIEA or NEt₃. When

the leaving group is suitable for metal-catalyzed couplings (preferably bromo or trifluoromethanesulfonyloxy), a number of cross-coupling reactions (such as Suzuki or Stille reactions) may be performed to introduce aryl, heteroaryl, alkenyl or cycloalkenyl groups (for reviews, see N. Miyaura, A. Suzuki, *Chem. Rev.*, 95:2457 (1995), J. K. Stille, *Angew. Chem, Int. Ed. Engl.*, 25: 508024 (1986) and A. Suzuki in *Metal-Catalyzed Coupling Reactions*, F. Deiderich, P. Stang, Eds., Wiley-VCH, Weinheim (1988)). Metal-catalyzed cross-couplings (preferably Suzuki reactions using a boronic acid or boronic ester) can be performed according to standard methodology, preferably in the presence of a palladium catalyst such as tetrakis(triphenylphosphine) Pd⁰ (Pd(PPh₃)₄), an aqueous base such as aq. Na₂CO₃, and a suitable solvent such as toluene, ethanol, DME, or DMF. Other metal-catalyzed coupling reactions that can be employed include aromatic and heteroaromatic amination and amidation (for reviews, see references for amination chemistry cited above for conversion of Formulas 1-1 to 1-2.)


[0055] In some cases, the initial substituents formed can be further derivatized as described below to provide the final substitution of Formula I.

[0056] Finally it is understood that substituents on compounds of Formula 1-4 may be further derivatized to provide compounds of Formula 1-5. Protecting groups on compounds of Formula 1-4 can be removed according to standard synthetic methodologies (see Theodora W. Greene and Peter G. M. Wuts, John Wiley and Sons, Inc., NY (1991)) and can be then subjected to further derivatization. Examples of further derivatization of compounds of 1-4 to provide compounds of Formulae 1-5 include, but are not limited to: when compounds of Formula 1-4 contain a primary or secondary amine, the amine may be reacted with aldehydes or ketones in the presence of a reducing agent such as sodium triacetoxyborohydride (see Abdel-Magid reference above) to reductively alkylate the amine; with acid chlorides or carboxylic acids and an amide bond forming reagent as described above to form amides; with sulfonyl chlorides to form sulfonamides; with isocyanates or carbamyl chlorides to form ureas; with aryl or heteroaryl halides in the presence of a palladium catalyst as described above (see Buchwald and Hartwig references above) to attach aryl and heteroaryl groups to the amines. In addition, when compounds of Formulae 1-4 contain an aryl or heteroaryl halide (preferably bromide) or an aryl or heteroaryl trifluoromethanesulfonyloxy group, these compounds may be further subjected to


metal-catalyzed reactions with boronic acids (for example, Suzuki or Stille couplings as described above) to attach aryl or heteroaryl groups, or with amines, alcohols or thiols (Buchwald- or Hartwig-type couplings, see Buchwald and Hartwig references above) to attach various amino, alkoxy, aryloxy, alkylthio or arylthio groups. When compounds of Formulae 1-4 contain a cyano group, this group may be hydrolyzed to amides or acids under acid or basic conditions. The resulting acids may be coupled to amines to form amides using the methodology described above. Basic amines may be oxidized to N-oxides and conversely N-oxides may be reduced to basic amines. When compounds of Formula 1-4 contain a sulfide, either acyclic or cyclic, the sulfide can be further oxidized to the corresponding sulfoxides or sulfones. Sulfoxides can be obtained by oxidation using an appropriate oxidant such as one equivalent of *meta*-chloroperoxybenzoic acid (MCPBA) or by treatment with NaIO₄ (see, for example, J. Regan, *et al*, *J. Med. Chem.*, 46: 4676-86 (2003)) and sulfones can be obtained using two equivalents of MCPBA or by treatment with 4-methylmorpholine N-oxide and catalytic osmium tetroxide (see, for example, PCT application WO 01/47919).

Example 1

5-Cyano-furan-2-carboxylic acid [2-(4-acetylaminopiperidin-1-yl)-phenyl]-amide




a) 5-Cyano-furan-2-carboxylic acid



To 2.8 g of 2-formyl-5-furancarboxylic acid (20 mmol) and 2.7 g of hydroxylamine hydrochloride (40 mmol) under Ar was added and dry pyridine (50 mL). The mixture was heated to 85 °C, acetic anhydride (40 mL) was added and the mixture was stirred for 3 h. After cooling to 60 °C, water (250 mL) was added and the mixture was stirred at RT for 70 h. The mixture was acidified to pH 2 with concentrated hydrochloric acid and extracted with 3:1


dichloromethane-isopropanol (8 x 100 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over anhydrous sodium sulfate and concentrated *in vacuo* to afford the title compound as a tan solid (1.26 g, 46 %). ¹H-NMR (CD₃OD; 400 MHz): δ 14.05 (br s, 1H), 7.74 (d, 1H, J = 3.8 Hz), 7.42 (d, 1H, J = 3.8 Hz).

b) 4-Acetylamino-piperidinium acetate




To a solution of 4-aminopiperidine (524 μL, 5.00 mmol) in diethyl ether (20 mL) was added a solution of acetic anhydride (567 μL, 0.600 mmol) in diethyl ether (20 mL) over 10 minutes and the resulting mixture was stirred for 1 h at RT. The solid was collected on a Buchner funnel, washed with diethyl ether (50 mL), and dried under vacuum to give 867 mg (86%) of the title compound as a white solid. ¹H-NMR (400 MHz, CDCl₃): δ 7.82 (d, 1H, J=10.5 Hz), 4.20-4.16 (m, 1H), 3.78-3.71 (m, 2H), 3.45 (br s, 1H), 3.09 (m, 1H), 2.69 (m, 1H), 1.98 (s, 3H), 1.79 (s, 3H), 1.78-1.69 (m, 2H), 1.28-1.13 (m, 2H).

c) N-[1-(2-Nitro-phenyl)-piperidin-4-yl]-acetamide



To a flask was added 4-acetylamino-piperidinium acetate (as prepared in the previous step) (800 mg, 4.00 mmol), DMF (40 mL), 2-fluoro-1-nitrobenzene (422 μL, 4.00 mmol), triethylamine (836 μL, 6.00 mmol) and the mixture stirred at RT for 17 h. The solvents were removed *in vacuo* and the residue was purified by silica gel preparative TLC eluting with dichloromethane / hexane / acetonitrile (47.5 / 47.5 / 5 v:v:v) yielded 55 mg (5%) of the title compound as a crystalline orange solid. ¹H-NMR (400 MHz, CDCl₃): δ 8.18 (m, 1H), 8.09 (br d, 1H, J=7.2 Hz), 7.45 (m, 1H), 6.88 (m, 1H), 6.67 (m, 1H), 4.38 (m, 1H), 3.86-3.74 (m, 1H), 3.32 (m, 1H), 3.07 (m, 1H), 2.14 (s, 3H), 1.67-1.52 (m, 2H).

d) N-[1-(2-Amino-phenyl)-piperidin-4-yl]-acetamide




To a solution of *N*-[1-(2-nitro-phenyl)-piperidin-4-yl]-acetamide (as prepared in the previous step) (55 mg, 0.21 mmol) in methanol (10 mL) was added 10% palladium on carbon (50 mg) and the mixture stirred at RT for 1 h under hydrogen (1 atm). The mixture was filtered through a short column of Celite and the solvent removed *in vacuo* to yield 48 mg (100%) of the title compound as a purple solid. ¹H-NMR (400 MHz, CDCl₃): δ 6.82-6.67 (m, 4H), 4.44 (m, 1H), 3.78 (m, 1H), 3.35 (br s, 2H), 3.21 (m, 1H), 2.91 (m, 1H), 2.11 (s, 3H), 2.12-2.04 (m, 2H), 1.75 (br s, 1H), 1.41 (m, 2H). LC-MS (ESI, m/z): Calcd. for C₁₃H₂₀N₃O, 234.2 (M+H); found: 234.0.

e) 5-Cyano-furan-2-carboxylic acid [2-(4-acetylamino-piperidin-1-yl)-phenyl]-amide


To a solution of 5-cyano-furan-2-carboxylic acid (as prepared in step (a), this example, 58 mg, 0.42 mmol) in dichloromethane (10 mL) was added DMF (50 μL), and oxalyl chloride (40 μL, 0.46 mmol) and the mixture stirred for 1 h at RT. The solvents were removed *in vacuo*, the residue was then taken up into dichloromethane (5 mL). This solution was added to a stirred solution of *N*-[1-(2-amino-phenyl)-piperidin-4-yl]-acetamide (as prepared in the previous step) (48 mg / 0.21 mmol) and DIEA (110 μL, 0.63 mmol) in dichloromethane (5 mL). The mixture was stirred for 17 h at RT and poured into satd aq sodium bicarbonate (50 mL), and extracted with dichloromethane (3 x 30 mL). The organic layers were washed with water (20 mL), brine (20 mL), dried over Na₂SO₄ and concentrated *in vacuo*. Purification of the resulting residue by silica gel preparative TLC eluting with 10% methanol in dichloromethane yielded 23 mg (31%) of the title compound as a brown solid. ¹H-NMR (400 MHz, CDCl₃): δ 8.41 (br s, 1H), 8.36 (d, 1H, J=8.4 Hz), 7.66-7.64 (m, 2H), 7.42-7.36 (m, 2H), 7.29-7.20 (m, 3H), 7.23 (d, 1H, J=3.7 Hz), 7.20 (dd, 1H, J=1.2, 7.5 Hz), 6.71 (dd, 1H, J=0.7, 3.4 Hz), 6.65 (m, 1H). LC-MS (ESI, m/z): Calcd. for C₁₉H₂₁N₄O₃, 353.2 (M+H); found: 353.0.

Example 2

5-Cyano-1H-pyrrole-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide




a) 5-Formyl-1H-pyrrole-2-carboxylic acid ethyl ester




To DMF (1.3 mL, 17 mmol) cooled to 5-10 °C was added phosphorous oxychloride (1.5 mL) dropwise and the mixture was diluted with 1,2-dichloroethane (5 mL). The flask was then cooled to -10 °C and ethyl pyrrole-2-carboxylate (2.00 g, 14.4 mmol) in 1,2-dichloroethane (5 mL) was added dropwise over 5 min. The mixture was heated to reflux for 15 min, cooled to RT and ethyl acetate (15 mL), water (20 mL), and satd aq sodium bicarbonate (70 mL) were added. The layers were separated and the aqueous layer was extracted with diethyl ether (3 x 20 mL). The combined organic layers were washed with saturated sodium carbonate (50 mL), dried (Na_2SO_4) and the solvents were removed *in vacuo*. The resulting solid was purified by column chromatography on silica gel (300 g), eluting with 30% ethyl acetate in hexane to yield 1.0 g (42%) of the title compound as a pale yellow crystalline solid. $^1\text{H-NMR}$ (400 MHz, CDCl_3): δ 9.89 (br s, 1H), 9.67 (s, 1H), 6.95 (d, 1H, $J=4.1$ Hz), 6.94 (d, 1H, $J=4.1$ Hz), 4.38 (q, 2H, $J=7.1\text{Hz}$), 1.39 (t, 3H, $J=7.1$).

b) 5-(Hydroxyimino-methyl)-1H-pyrrole-2-carboxylic acid ethyl ester




A mixture of 5-formyl-1H-pyrrole-2-carboxylic acid ethyl ester (as prepared in the previous step, 300 mg, 1.80 mmol), hydroxylamine hydrochloride (560 mg, 8.10 mmol), ethanol (10 mL), sodium acetate (1.10 g, 13.4 mmol) and water (10 mL) was stirred at 90 °C for 30 min. The solvents were removed *in vacuo* and the solid was collected on a Buchner funnel and washed with water (10 mL) to yield 226 mg (69%) of the title compound as a white solid: LC-MS (ESI, m/z): Calcd. for $\text{C}_8\text{H}_{11}\text{N}_2\text{O}_3$, 183.1 (M+H); found: 183.0.

c) 5-Cyano-1H-pyrrole-2-carboxylic acid ethyl ester




A solution of 5-(hydroxyimino-methyl)-1H-pyrrole-2-carboxylic acid ethyl ester (as prepared in the previous step) (500 mg, 2.75 mmol) in acetic anhydride (5 mL) was stirred at 140 °C for 2 h. The cooled mixture was quenched with ice and then dichloromethane was added and the mixture was made basic with solid sodium bicarbonate. The layers were separated, the organic layer was washed with saturated sodium bicarbonate (2 x 10 mL), water (2 x 10 mL), then dried over Na₂SO₄. The solvent was removed *in vacuo* to yield 260 mg (58%) of the title compound as a light brown crystalline solid. ¹H-NMR (400 MHz, CDCl₃): δ 10.45 (br s, 1H), 6.89 (m, 1H), 6.83 (m, 1H), 4.42 (q, 2H, J=7.2 Hz), 1.40 (t, 3H, J=7.1 Hz).

d) 5-Cyano-1H-pyrrole-2-carboxylic acid



To 260 mg of 5-cyano-1H-pyrrole-2-carboxylic acid ethyl ester (as prepared in the previous step) (1.59 mmol) in ethanol (6 mL) was added 1M aq sodium hydroxide (3.00 mL, 3.00 mmol) and the mixture was stirred at 80 °C for 2.5 h. The solvent was removed *in vacuo*, and the resulting solution was acidified to pH 3 with concentrated hydrochloric acid. The solid was collected on a filter and washed with water (1 mL) and dried under high vacuum to yield the title compound as a light tan solid which was used without further purification in the following step.

e) 5-Cyano-1H-pyrrole-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide




To 24.5 mg (0.180 mmol) 5-cyano-1H-pyrrole-2-carboxylic acid (as prepared in the previous step) in dichloromethane (10 mL) was added 53 mg (0.28 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), hydroxybenzotriazole (HOBt, 30 mg, 0.22 mmol), and 2-piperidinoaniline (38 mg, 0.22 mmol) and the mixture stirred for 6.5 h at RT. The mixture was poured into brine (50 mL) and extracted with dichloromethane (3 x 20 mL). The organic layers were washed with brine (20 mL), dried over Na_2SO_4 and the solvent was removed *in vacuo*. Purification of the resulting residue by silica gel preparative TLC eluting with 30% ethyl acetate in hexane yielded 24 mg (42%) of the title compound as a brown solid.

$^1\text{H-NMR}$ (400 MHz, CDCl_3): δ 11.90 and 10.45 (br s, 1H, rotomers), 9.60 and 9.38 (s, 1H, rotomers), 8.60 and 8.47 (d, 1H, $J=7.9$ Hz, rotomers), 7.29-6.74 (m, 5H), 2.85 (m, 4H), 1.78-1.68 (m, 6H). LC-MS (ESI, m/z): Calcd. for $\text{C}_{17}\text{H}_{19}\text{N}_4\text{O}$, 295.2 ($\text{M}+\text{H}$); found: 295.2.

Example 3

5-Cyano-furan-2-carboxylic acid (4-methoxy-2-piperidin-1-yl-phenyl)-amide



a) 1-(5-Chloro-2-nitro-phenyl)-piperidine

To a cooled (0°C) solution of 1.75 g (10.0 mmol) of 4-chloro-2-fluoronitrobenzene in 15 mL of EtOH was added 2.97 mL (30.0 mmol) of piperidine dropwise over 5 min. The solution stirred at 0°C for 10 min and then at 23°C for 30 min. The mixture was poured into water (225 mL) and extracted with EtOAc (2 x 30 mL). The combined extracts were washed with saturated aq NaHCO_3 and brine (30 mL each) and then dried (Na_2SO_4). Concentration afforded 2.33 g

(97%) of the title compound as an orange oil which crystallized on standing: Mass spectrum (ESI, m/z): Calcd. for $C_{11}H_{13}ClN_2O_2$, 241.1 (M+H), found 241.1.

b) 1-(5-Methoxy-2-nitro-phenyl)-piperidine

To 1-(5-chloro-2-nitro-phenyl)-piperidine (197 mg, 0.810 mmol) in 1.5 mL of DMF was added 4 mL of 0.5 M NaOMe in MeOH (2.5 eq). The resultant solution was heated at 60 °C overnight, then at 90 °C for 24 h. The reaction was diluted with EtOAc (50 mL) and washed with water (50 mL), dried (Na_2SO_4) and concentrated in vacuo. Purification by preparative TLC (20% EtOAc-hexane) gave 80 mg (41%) of the title compound, along with 80 mg (40%) of recovered starting material. ^1H -NMR ($CDCl_3$; 400 MHz): δ 7.95 (d, 1H, J = 9.1 Hz), 6.51 (d, 1H, J = 2.6 Hz), 6.46 (dd, 1H, J = 2.6, 9.1 Hz), 3.87 (s, 3H), 3.01-3.04 (m, 4H), 1.72-1.78 (m, 4H), 1.60-1.64 (m, 2H).

c) 4-Methoxy-2-piperidin-1-yl-phenylamine


1-(5-methoxy-2-nitro-phenyl)-piperidine (80 mg, 0.33 mmol, as prepared in the previous step) was stirred with 55 mg of 5% Pd-C in MeOH (4 mL) under H_2 balloon pressure for 2 h. The reaction was filtered through Celite and concentrated *in vacuo* to afford 67 mg (98%) of the title compound as a reddish solid, which was used immediately without further purification. Mass spectrum (ESI, m/z): Calcd. for $C_{12}H_{18}N_2O$, 207.1 (M+H), found 207.2.

d) 5-Cyano-furan-2-carboxylic acid (4-methoxy-2-piperidin-1-yl-phenyl)-amide

Using a procedure similar to Example 1, step (e), 5-cyano-furan-2-carbonyl chloride (66 mg, 0.43 mmol) was allowed to react with 4-methoxy-2-piperidin-1-yl-phenylamine (67 mg, 0.32 mmol, as prepared in the previous step) in the presence of DIEA (164 μ L, 0.940 mmol) for 2 h to afford 62 mg (60%) of the title compound as a yellow solid. ^1H -NMR ($CDCl_3$; 400 MHz): δ 9.49 (br s, 1H) 8.35 (d, 1H, J = 8.9 Hz), 7.27-7.22 (m, 1H), 6.76 (d, 1H, J = 2.7 Hz), 6.71 (dd, 1H, J = 2.8, 8.9 Hz), 3.81 (s, 3H), 2.85-2.83 (m, 4H), 1.84-1.78 (m, 4H), 1.66-1.65 (m, 2H); Mass spectrum (ESI, m/z): Calcd. for $C_{18}H_{19}N_3O_3$, 326.1 (M+H), found 326.1.

Example 4

5-Cyano-furan-2-carboxylic acid (4-imidazol-1-yl-2-piperidin-1-yl-phenyl)-amide



a) 1-(5-Imidazol-1-yl-2-nitro-phenyl)-piperidine

To 1-(5-chloro-2-nitro-phenyl)-piperidine (184 mg, 0.760 mmol, as prepared in Example 3, step (a)) and imidazole (67.8 mg, 0.99 mmol) in 3 mL of DMSO was added KOH (64 mg, 1.1 mmol). The reaction was heated to 90 °C overnight. The dark solution was poured into 40 mL of water and extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with water (50 mL), dried (Na₂SO₄) and concentrated in vacuo to give 190 mg (92%) of the title compound as a yellow solid. Mass spectrum (ESI, *m/z*): Calcd. for C₁₄H₁₆N₄O₂, 273.1 (M+H), found 273.1.

b) 4-Imidazol-1-yl-2-piperidin-1-yl-phenylamine

To 1-(5-imidazol-1-yl-2-nitro-phenyl)-piperidine (117 mg, 0.430 mmol, as prepared in the previous step) in 3 mL of THF was added 6.5 mL of 10% TiCl₃ in H₂O dropwise over 3 min. After 10 min, the reaction was extracted with 20 mL of EtOAc, and the organic layer was discarded. The aqueous layer was basified with 10M NaOH to pH>9, then extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (20 mL), dried (Na₂SO₄), and concentrated in vacuo to afford 74 mg (66%) of the title compound as a light brown solid. Mass spectrum (ESI, *m/z*): Calcd. for C₁₄H₁₈N₄, 243.1 (M+H), found 243.2;


c) 5-Cyano-furan-2-carboxylic acid (4-imidazol-1-yl-2-piperidin-1-yl-phenyl)-amide

Using a procedure similar to Example 3, step (d), 4-imidazol-1-yl-2-piperidin-1-yl-phenylamine (69 mg, 0.28 mmol, as prepared in the previous step) was allowed to react with 5-

cyano-furan-2-carbonyl chloride (56 mg, 0.36 mmol) in the presence of DIEA (138 μ L, 0.790 mmol) to afford 44.9 mg (44%) of the title compound as a yellow solid. $^1\text{H-NMR}$ (CDCl_3 ; 400 MHz): δ 9.65 (br s, 1H), 8.57 (d, 1H, $J = 9.3$ Hz), 7.84 (s, 1H), 7.34 (d, 1H, $J = 3.7$ Hz), 7.28-7.27 (m, 2H), 7.22-7.20 (m, 3H), 2.93-2.90 (m, 4H), 1.88-1.85 (m, 4H), 1.72 (br s, 2H); Mass spectrum (ESI, m/z): Calcd. for $\text{C}_{20}\text{H}_{19}\text{N}_5\text{O}_2$, 362.1 ($\text{M}+\text{H}$), found 362.2.

Example 5

5-Cyano-furan-2-carboxylic acid (4-dimethylamino-2-piperidin-1-yl-phenyl)-amide



a) 1-(5-Fluoro-2-nitro-phenyl)-piperidine

To a solution of 2,4-difluoronitrobenzene (2.09 g, 13.1 mmol) in EtOH (10 mL) at ambient temperature was added piperidine (3.35 g, 39.4 mmol) dropwise. The reaction was allowed to stir overnight and concentrated in vacuo. The residue was dissolved in EtOAc (100 mL), washed with water (2 x 100 mL), dried (Na_2SO_4) and concentrated in vacuo. Purification by silica gel column chromatography afforded 1.10 (37%) of the title compound as an oil. Mass spectrum (ESI, m/z): Calcd. for $\text{C}_{11}\text{H}_{13}\text{FN}_2\text{O}_2$, 225.1 ($\text{M}+\text{H}$), found 225.1.

b) Dimethyl-(4-nitro-3-piperidin-1-yl-phenyl)-amine

To a solution of 1-(5-fluoro-2-nitro-phenyl)-piperidine (294 mg, 1.31 mmol, as prepared in the previous step) in 8 mL EtOH-DMF (v/v) was added NaCN (128 mg, 2.6 mmol). The reaction was heated to 130 $^\circ\text{C}$ in a sealed tube for 24 h. The reaction was diluted with EtOAc (50 mL) and washed with water (2 x 50 mL). Chromatography (50% EtOAc-hexane) of the crude product afforded 88 mg (27%) the title compound as well as 78 mg (24%) (1-(5-ethoxy-2-nitro-phenyl)-piperidine as yellow solids. Mass spectrum (ESI, m/z): Calcd. for $\text{C}_{13}\text{H}_{19}\text{N}_3\text{O}_2$, 250.1 ($\text{M}+\text{H}$), found 250.0.

c) 4-*N,N*-Dimethyl-2-piperidin-1-yl-benzene-1,4-diamine


Using a procedure similar to Example 3, step (c), dimethyl-(4-nitro-3-piperidin-1-yl-phenyl)-amine (100 mg, 0.4 mmol, as prepared in the previous step) was stirred with 80 mg 5% Pd-C in 5 mL MeOH under H₂ to afford 89 mg (100%) of the title compound as an oil, which was used immediately without further purification. Mass spectrum (ESI, *m/z*) calcd. for C₁₃H₂₁N₃, 220.1 (M+H), found 220.1.

d) 5-Cyano-furan-2-carboxylic acid (4-dimethylamino-2-piperidin-1-yl-phenyl)-amide

Using a procedure similar to Example 3, step (d), 4-*N,N*-dimethyl-2-piperidin-1-yl-benzene-1,4-diamine (89 mg, 0.4 mmol, as prepared in the previous step) was allowed to react with 5-cyano-furan-2-carbonyl chloride (236 mg, 1.5 mmol) in the presence of DIEA (0.15 mL, 0.88 mmol) to afford 84.7 mg (63%) of the title compound as a yellow powder. ¹H-NMR (CDCl₃, 400 MHz): δ 9.50 (br s, 1H), 8.29 (d, 1H, *J* = 8.9 Hz), 7.21-7.24 (m, 2H), 6.58 (d, 1H, *J* = 2.7 Hz), 6.54 (dd, 1H, *J* = 2.8, 9.0 Hz), 2.95 (s, 6H), 2.84-2.87 (m, 4H), 1.78-1.82 (m, 4H), 1.65 (br s, 2H); Mass spectrum (ESI, *m/z*): Calcd. for C₁₉H₂₂N₄O₂, 339.1 (M+H), found 339.1.

Example 6

5-Cyano-furan-2-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-phenyl]-amide



a) 4,4-Difluoro-1-(2-nitro-phenyl)-piperidine

To a mixture of 2-fluoro-nitrobenzene (116 mg, 0.82 mmol) and 4-difluoropiperidine hydrochloride salt (142 mg, 0.9 mmol) in 3 mL of DMF was added Cs₂CO₃ (731 mg, 2.2 mmol). The reaction was heated to 80 °C for 4 h. At this time the mixture was poured into water (20 mL) and then extracted with CHCl₃ (2 x 50mL). The organic layers were dried (Na₂SO₄) and

concentrated in vacuo to give 128 mg (64%) of a yellow solid and used without further purification. Mass spectrum (ESI, m/z): Calcd. for $C_{11}H_{12}F_2N_2O_2$, 243.0 (M+H), found 243.2.

b) 2-(4,4-Difluoro-piperidin-1-yl)-phenylamine


Using a procedure similar to Example 3, step (c), 4,4-difluoro-1-(2-nitro-phenyl)-piperidine (128 mg, 0.520 mmol, as prepared in the previous step) was stirred with 80 mg 5% Pd-C in 4 mL of MeOH under H_2 to afford 76 mg (69%) of the title compound as a dark oil, which was used immediately due to apparent instability. Mass spectrum (ESI, m/z): Calcd. for $C_{11}H_{14}F_2N_2$, 213.1 (M+H), found 213.1.

c) 5-Cyano-furan-2-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-phenyl]-amide

Using a procedure similar to Example 3, step (d), 2-(4,4-difluoro-piperidin-1-yl)-phenylamine (76 mg, 0.35 mmol) was allowed to react with 5-cyano-furan-2-carbonyl chloride (62 mg, 0.40 mmol) in the presence of DIEA (134 μ L, 0.770 mmol) to afford 42 mg (36%) of the title compound as a tan solid. ^1H -NMR ($CDCl_3$; 400 MHz): δ 9.60 (br s, 1H), 8.44 (dd, 1H, J = 1.3, 8.1 Hz) 7.32 (d, 1H, J = 3.8 Hz), 7.27-7.21 (m, 3H), 7.18-7.13 (m, 1H), 3.07-3.04 (m, 4H), 2.29-2.21 (m, 4H); Mass spectrum (ESI, m/z): Calcd. for $C_{17}H_{15}F_2N_3O_2$, 332.1 (M+H), found 332.1.

Example 7

5-Cyano-furan-2-carboxylic acid (4-ethoxy-2-piperidin-1-yl-phenyl)-amide



a) 1-(5-Ethoxy-2-nitro-phenyl)-piperidine

To 1-(5-chloro-2-nitro-phenyl)-piperidine (197 mg, 0.810 mmol, as prepared in Example 3, step (a)) in 1.5 mL of DMF was added 4 mL of 0.5 M NaOEt in EtOH (1.94 mmol). The

resultant solution was heated at 90 °C for 24 h. The reaction was diluted with EtOAc (50 mL) and washed with water (50 mL), dried (Na₂SO₄) and concentrated in vacuo. Purification by preparative tlc (20% EtOAc-hexane) gave 110 mg (54%) of the title compound. Mass spectrum (ESI, *m/z*): Calcd. for C₁₃H₁₈N₂O₃, 251.1 (M+H), found 251.1.

b) 4-Ethoxy-2-piperidin-1-yl-phenylamine


Using a procedure similar to Example 3, step (c), 1-(5-ethoxy-2-nitro-phenyl)-piperidine (78 mg, 0.31 mmol, as prepared in the previous step) was stirred with 42 mg of 5% Pd-C under H₂ to afford 64 mg (94%) of the title compound which was used immediately without further purification. Mass spectrum (ESI, *m/z*): Calcd. for C₁₃H₂₀N₂O, 221.1 (M+H), found 221.1.

c) 5-Cyano-furan-2-carboxylic acid (4-ethoxy-2-piperidin-1-yl-phenyl)-amide

Using a procedure similar to Example 3, step (d), 4-ethoxy-2-piperidin-1-yl-phenylamine (64 mg, 0.29 mmol, as prepared in the previous step) was allowed to react with 5-cyano-furan-2-carboxyl chloride (66.6 mg, 0.430 mmol) in the presence of DIEA (111 µL, 0.63 mmol) to afford 53 mg (54%) of the title compound as a light yellow solid. ¹H-NMR (CDCl₃, 400 MHz): δ 9.49 (br s, 1H), 8.32 (d, 1H, J = 8.9 Hz), 7.25 (d, 1H, J = 2.7 Hz), 7.22 (d, 1H, J = 2.8 Hz), 6.77 (d, 1H, J = 2.8 Hz), 6.67 (dd, 1H, J=2.8, 8.9 Hz), 2.82 (m, 4H), 4.02 (q, 2H, J = 7.0 Hz), 2.82 (m, 4H), 1.80-1.82 (m, 4H), 1.64 (br s, 2H), 1.41 (t, 3H, J = 7.0 Hz); Mass spectrum (ESI, *m/z*): Calcd. for C₁₉H₂₁N₃O₃, 340.1 (M+H), found 340.1.

Example 8

5-Cyano-furan-2-carboxylic acid (3-chloro-2-piperidin-1-yl-phenyl)-amide



a) 1-(2-Chloro-6-nitro-phenyl)-piperidine

To a flask containing 2,3-dichloronitrobenzene (387 mg, 2.01 mmol) was added 3 mL of piperidine, and the result was heated to 80 °C overnight. The reaction was diluted with EtOAc (30 mL), washed with water (2 x 30 mL), dried (Na_2SO_4) and concentrated in vacuo. Purification by preparative tlc (20% EtOAc-hexane) yielded 320 mg (66%) of the title compound as a yellow solid. $^1\text{H-NMR}$ (CDCl_3 ; 400 MHz): δ 7.56-7.50 (m, 2H), 7.04 (t, 1H, $J = 8.1$ Hz), 3.04 (br s, 4H), 1.69 (br s, 4H), 1.59 (br s obscured by water, 2H).

b) 3-Chloro-2-piperidin-1-yl-phenylamine


Using a procedure similar to Example 3, step (c), 1-(2-chloro-6-nitro-phenyl)-piperidine (79 mg, 0.32 mmol, as prepared in the previous step) was stirred with 44 mg of 5% Pd-C under H_2 for 1h 30 min to afford 54 mg (80%) of the title compound, contaminated with the des-chloro derivative, which was used immediately without further purification. Mass spectrum (ESI, m/z): Calcd. for $\text{C}_{11}\text{H}_{15}\text{ClN}_2$, 211.0 (M+H), found 211.1.

c) 5-Cyano-furan-2-carboxylic acid (3-chloro-2-piperidin-1-yl-phenyl)-amide

Using a procedure similar to Example 3, step (d), 3-chloro-2-piperidin-1-yl-phenylamine (54 mg, 0.25 mmol, as prepared in the previous step) was allowed to react with 5-cyano-furan-2-carboxyl chloride (55.8 mg, 0.360 mmol) in the presence of DIEA (95 μL , 0.55 mmol) to afford 8.4 mg (10%) of the title compound as a yellow solid. $^1\text{H-NMR}$ (CDCl_3 ; 400 MHz): δ 10.70 (br s, 1H), 8.42 (dd, 1H, $J = 1.4, 8.1$ Hz), 7.30 (dd, $J = 1.5, 3.7$ Hz), 7.24 (d, 1H, $J = 3.7$ Hz), 7.17 (t, 1H, $J = 8.1$ Hz), 7.07 (dd, 1H, $J = 1.4, 8.1$ Hz), 3.58-3.52 (m, 2H), 2.85-2.82 (m, 2H), 2.02-1.99 (m, 1H), 1.89-1.72 (m, 4H), 1.52-1.38 (m, 1H), Mass spectrum (ESI, m/z): Calcd. for $\text{C}_{17}\text{H}_{16}\text{ClN}_3\text{O}_2$, 330.0 (M+H), found 330.1.

Example 9

5-Cyano-furan-2-carboxylic acid (3-methyl-2-piperidin-1-yl-phenyl)-amide



a) 1-(2-Methyl-6-nitro-phenyl)-piperidine

Using a procedure similar to Example 8, step (a), 2-chloro-3-methylnitrobenzene (264 mg, 1.53 mmol) was heated to 110 °C overnight in 3 mL of piperidine to afford 128 mg (35%) of the title compound and an undetermined amount of starting material. ¹H-NMR (CDCl₃; 400 MHz): δ 7.41-7.34 (m, 2H), 7.02 (t, 1H, J = 7.7 Hz), 2.96-2.93 (m, 4H), 2.36 (s, 3H), 1.65 (br s, 6H).

b) 3-Methyl-2-piperidin-1-yl-phenylamine


Using a procedure similar to Example 3, step (c), 1-(2-methyl-6-nitro-phenyl)-piperidine (74 mg, 0.38 mmol, as prepared in the previous step) was stirred with 5% Pd-C (50 mg) under H₂ to afford 66mg (91%) of the title compound as an oil. Mass spectrum (ESI, *m/z*): Calcd. for C₁₂H₁₈N₂, 191.1 (M+H), found 191.1.

c) 5-Cyano-furan-2-carboxylic acid (3-methyl-2-piperidin-1-yl-phenyl)-amide

Using a procedure similar to example 3, step (d), 3-methyl-2-piperidin-1-yl-phenylamine (68 mg, 0.35 mmol, as prepared in the previous step) was allowed to react with 5-cyano-furan-2-carboxyl chloride (65 mg, 0.42 mmol) in the presence of DIEA (134 μL, 0.77 mmol) to afford 13 mg (12%) of the title compound as a waxy yellow solid. ¹H-NMR (CDCl₃, 400 MHz): δ 10.7 (br s, 1H), 8.33 (d, 1H, J = 8.0 Hz), 7.27 (d, 1H, J = 3.7 Hz), 7.22 (dd, 1H, 3.7 Hz), 7.12 (t, 1H, J = 7.9 Hz), 6.87 (dd, 1H, J = 0.7, 7.7 Hz), 3.22-3.28 (m, 2H), 2.88-2.91 (m, 1H), 2.41 (s, 3H), 2.01-2.04 (m, 1H), 1.80-1.86 (m, 4H), 1.43-1.47 (m, 1H); Mass spectrum (ESI, *m/z*): Calcd. for C₁₈H₁₉N₃O₂, 310.1 (M+H), found 310.2.

Example 10

5-Cyano-furan-2-carboxylic acid (2-piperidin-1-yl-4-pyrazol-1-yl-phenyl)-amide



a) 1-(2-Nitro-5-pyrazol-1-yl-phenyl)-piperidine


Using a procedure similar to Example 4, step (a), a solution of 1-(5-fluoro-2-nitro-phenyl)-piperidine (98 mg, 0.43 mmol, as prepared in Example 5, step (a)), pyrazole (67.8 mg, 0.600 mmol), and NaOH (22.4 mg, 0.560 mmol) were heated in 3 mL of DMSO overnight to afford 100 mg (85%) the title compound as a yellow solid. Mass spectrum (ESI, m/z): Calcd. for $C_{14}H_{16}N_4O_2$, 273.1 (M+H), found 273.1.

b) 5-Cyano-furan-2-carboxylic acid (2-piperidin-1-yl-4-pyrazol-1-yl-phenyl)-amide

Using a procedure similar to Example 4, step (b), 1-(2-nitro-5-pyrazol-1-yl-phenyl)-piperidine (100 mg, 0.31 mmol, as prepared in the previous step) was allowed to react with $TiCl_3$ (1.80 mL, 2.94 mmol) in 3 mL of THF to afford 72 mg (94%) of 2-piperidin-1-yl-4-pyrazol-1-yl-phenylamine, which was allowed to react in a manner similar to Example 3, step (d), with 5-cyano-furan-2-carboxyl chloride (67.5 mg, 0.43 mmol) in the presence of DIEA (111 μ L, 0.6 mmol) to afford 52.7 mg (47%) of the title compound as a light yellow solid. ^1H -NMR ($CDCl_3$; 400 MHz): δ 9.67 (s, 1H), 8.50 (d, 1H, J = 8.8 Hz), 7.90 (d, 1H, J = 2.4 Hz), 7.71 (d, 1H, J = 1.5 Hz), 7.65 (d, 1H, J = 2.4 Hz), 7.37 (dd, 1H, J = 2.5, 8.8 Hz), 7.29 (d, 1H, J = 3.8 Hz), 7.23 (d, 1H, J = 3.7 Hz), 6.46-6.45 (m, 1H), 2.92-2.89 (m, 4H), 1.85-1.80 (m, 4 H), 1.66 (br s, 2H); Mass spectrum (ESI, m/z): Calcd. for $C_{20}H_{19}N_5O_2$ 362.1 (M+H), found 362.2.

Example 11

5-Cyano-furan-2-carboxylic acid [4-(acetyl-methyl-amino)-2-piperidin-1-yl-phenyl]-amide



a) N-Methyl-(4-nitro-3-piperidin-1-yl-phenyl)-amine

A solution of 1-(5-fluoro-2-nitro-phenyl)-piperidine (200 mg, 0.89 mmol, as prepared in Example 5, step (a)) in 4 mL of 2M methylamine in MeOH was heated in a sealed tube for 12 h at 80 °C. solvent under vacuum afforded methyl-(4-nitro-3-piperidin-1-yl-phenyl)-amine (209 mg, 100%). Mass spectrum (ESI, m/z): Calcd. for $C_{12}H_{17}N_3O_2$, 236.1 (M+H), found 236.1.

b) N-Methyl-N-(4-nitro-3-piperidin-1-yl-phenyl)-acetamide

To a solution of methyl-(4-nitro-3-piperidin-1-yl-phenyl)-amine (80 mg, 0.34 mmol, as prepared in the previous step) and triethylamine (118 μ L, 0.850 mmol) in 4 mL of CH_2Cl_2 was added acetic anhydride (320 μ L, 3.40 mmol) via microsyringe and the reaction was allowed to stir overnight. At this time it was diluted with $CHCl_3$ (50 mL), washed with satd aq $NaHCO_3$ (2 x 50 mL), and dried (Na_2SO_4). Concentration of the solvent in vacuo and purification of the crude material using preparative TLC (4% MeOH- $CHCl_3$) afforded 67 mg (71%) of the title compound as an oil. Mass spectrum (ESI, m/z): Calcd. for $C_{14}H_{19}N_3O_3$, 278.1 (M+H), found 278.1.


c) 5-Cyano-furan-2-carboxylic acid [4-(acetyl-methyl-amino)-2-piperidin-1-yl-phenyl]-amide

Using a procedure similar to Example 3, step (c), *N*-methyl-*N*-(4-nitro-3-piperidin-1-yl-phenyl)-acetamide (67 mg, 0.24 mmol, as prepared in the previous step) was stirred with 5% Pd-C (45 mg) under H_2 to afford *N*-(4-amino-3-piperidin-1-yl-phenyl)-*N*-methyl-acetamide which was used immediately. Using a procedure similar to Example 3, step (d) this was coupled to 5-cyano-furan-2-carbonyl chloride (52 mg, 0.33 mmol) in the presence of DIEA (107 μ L, 0.55 mmol) to afford 7.3 mg (8 %) of the title compound as a waxy solid. ^1H -NMR ($CDCl_3$; 400

MHz): δ 9.66 (s, 1H), 8.48 (d, 1H, $J = 9.2$ Hz), 7.34 (d, 1H, $J = 3.7$ Hz), 7.26 (d, 1H, $J = 3.3$ Hz), 7.03-7.01 (m, 2H), 3.27 (s, 3H), 2.88-2.86 (m, 4H), 1.90 (s, 3H), 1.88-1.82 (m, 4H), 1.63 (br s, 2H); Mass spectrum (ESI, m/z): Calcd. for $C_{20}H_{22}N_4O_3$, 367.1 ($M+1$), found 367.2.

Example 12

5-Cyano-furan-2-carboxylic acid (4-acetyl-amino-2-piperidin-1-yl-phenyl)-amide



a) Methyl-(4-nitro-3-piperidin-1-yl-phenyl)-amine

A solution of 1-(5-fluoro-2-nitro-phenyl)-piperidine (200 mg, 0.89 mmol) in 4 mL of 2M methylamine in MeOH was heated in a sealed tube for 12 h at 80 °C. Removal of the solvent under vacuum afforded methyl-(4-nitro-3-piperidin-1-yl-phenyl)-amine (209 mg, 100%). Mass spectrum (ESI, m/z): Calcd. for $C_{12}H_{17}N_3O_2$, 236.1 ($M+H$), found 236.1.

b) N-(4-Amino-3-piperidin-1-yl-phenyl)-acetamide


4-Nitro-3-piperidin-1-yl-phenylamine (64 mg, 0.28 mmol, as prepared in the previous step) and DIEA (122 μ L, 0.700 mmol) in 4 mL of CH_2Cl_2 was treated with acetyl chloride (28 μ L, 0.40 mmol). The reaction was stirred for 1 h, diluted with CH_2Cl_2 (25 mL), washed with water (50 mL), and dried (Na_2SO_4). Concentration of the solvent in vacuo afforded 51 mg (78 %) of N-(4-nitro-3-piperidin-1-yl-phenyl)-acetamide. Using a procedure similar to Example 3, step (c), 4-nitro-3-piperidin-1-yl-phenylamine (51 mg, 0.21 mmol) was stirred with 5% Pd-C (35 mg) under H_2 to afford 40 mg (61%) of the title compound as a dark semi-solid. Mass spectrum (ESI, m/z): Calcd. for $C_{13}H_{19}N_3O$, 234.1 ($M+H$), found 234.2.

c) 5-Cyano-furan-2-carboxylic acid (4-acetyl-amino-2-piperidin-1-yl-phenyl)-amide


Using a procedure similar to Example 3, step (d), *N*-(4-amino-3-piperidin-1-yl-phenyl)-acetamide (40 mg, 0.17 mmol, as prepared in the previous step) was allowed to react with 5-cyano-furan-2-carbonyl chloride (27 mg, 0.17 mmol) in the presence of DIEA (65 μ L, 0.37 mmol) to afford 23 mg (38%) of the title compound as a yellow solid. $^1\text{H-NMR}$ (CDCl_3 ; 400 MHz): δ 9.64 (s, 1H), 8.36 (d, 1H, $J = 8.5$ Hz), 7.70 (br s, 1H), 7.27 (br s, 1H), 7.22 (d, 1H, $J = 3.8$ Hz), 7.14 (br s, 1H), 7.02 (dd, 1H, $J = 6.6, 8.9$ Hz), 2.85 (br s, 4H), 2.18 (s, 3H), 1.80 (br s, 4H), 1.65 (br s, 2H); Mass spectrum (ESI, m/z): Calcd. for $\text{C}_{19}\text{H}_{20}\text{N}_4\text{O}_3$, 353.1 (M^+), found 353.2.

Example 13

5-Cyano-furan-2-carboxylic acid [2-(4-methyl-piperidin-1-yl)-4-pyridin-4-yl-phenyl]-amide bis(trifluoroacetic acid salt).




a) 1-(5-Bromo-2-nitro-phenyl)-4-methyl-piperidine



A solution of 4-bromo-2-fluoro-phenylamine (3.00 g, 15.8 mmol) in 15 mL of DCM is added drop wise to a suspension of 3-chloroperoxybenzoic acid (19 g, 57-86%) in 200 mL of DCM at -10°C and the mixture is allowed to attain RT and stirred for 10 h. The reaction is then washed with saturated aqueous NaHCO_3 (2 x 150 mL) and brine (100 mL), and the organic layer dried over Na_2SO_4 and evaporated. MeOH (10 mL) was then added to the crude residue to precipitate a white solid that was removed by filtration and the filtrate was concentrated to give


4-bromo-2-fluoro-1-nitro-benzene. This product was dissolved in 100 mL of DCM, cooled to 0 °C, and 4-methylpiperidine (5.00 g, 50.8 mmol) was added and the solution was stirred for 10 h at RT. The reaction was diluted with 100 mL of DCM, washed with brine (3 x 100 mL), and the organic layer dried over Na₂SO₄ and concentrated. The crude oil was purified by elution from a 20-g solid phase extraction (SPE) cartridge (silica) with 50% DCM/hexanes to give 3.4 g (72 %) of the title compound as a yellow oil: Mass spectrum (ESI, m/z): Calcd. for C₁₂H₁₅BrN₂O₂, 299.0 (M+H), found 299.1.

b) 4-Bromo-2-(4-methyl-piperidin-1-yl)-phenylamine




A flask charged with 1-(5-bromo-2-nitro-phenyl)-4-methyl-piperidine (1.0 g, 3.3 mmol) (as prepared in the previous step), ammonium chloride (1.8 g, 33 mmol), iron powder (0.93 g, 16 mmol), EtOH (12 mL) and water (6 mL) was heated at 80 °C for 1 h. The reaction was filtered through Celite, concentrated and eluted from a 20-g SPE cartridge (silica) with 100% DCM to give 0.80 g (91%) of the title compound as a yellow oil. Mass spectrum (ESI, m/z): Calcd. for C₁₂H₁₇BrN₂, 269.1/271.1 (M+H), found 269.1/271.1.

c) 5-Cyano-furan-2-carboxylic acid [4-bromo-2-(4-methyl-piperidin-1-yl)-phenyl]-amide



The title compound was obtained by coupling 4-bromo-2-(4-methyl-piperidin-1-yl)-phenylamine (as prepared in the previous step) to 5-cyano-furan-2-carboxylic acid (as prepared in Example 1, step (a)) according to the procedure in Example 1, step (e). Mass spectrum (ESI, m/z): Calcd. for C₁₈H₁₈BrN₃O₂, 388.1/390.1 (M+H), found 388.1/390.1.

d) Furan-2,5-dicarboxylic acid 2-amide 5-{{2-(4-methyl-piperidin-1-yl)-4-pyridin-4-yl-phenyl}-amide




A flask was charged with 5-cyano-furan-2-carboxylic acid [4-bromo-2-(4-methyl-piperidin-1-yl)-phenyl]-amide (0.048 g, 0.12 mmol) (as prepared in the previous step), pyridyl-4-boronic acid (0.022 g, 0.18 mmol), Pd(PPh₃)₄ (0.014 g, 10 mol%), 2M Na₂CO₃ (0.5 mL), and DMF (1 mL) and heated for 12 h at 75 °C. The reaction was diluted with EtOAc (10 mL) and washed with brine (2 x 10 mL). The organic layer was dried (Na₂SO₄) and concentrated and the title product (0.40 g, 83%) eluted from a 10-g SPE cartridge (silica) with 100% EtOAc. Mass spectrum (ESI, m/z): Calcd. for C₂₃H₂₄N₄O₂, 405.2 (M+H), found 405.2.

e) 5-Cyano-furan-2-carboxylic acid [2-(4-methyl-piperidin-1-yl)-4-pyridin-4-yl-phenyl]-amide bis(trifluoroacetic acid salt)


A flask charged with furan-2,5-dicarboxylic acid 2-amide 5-{{2-(4-methyl-piperidin-1-yl)-4-pyridin-4-yl-phenyl}-amide (0.040 g, 0.10 mmol) (as prepared in the previous step), pyridine (0.025 mL, 0.30 mmol), p-toluenesulfonyl chloride (0.030 g, 0.15 mmol), and DMF (1 mL) was heated for 2 h at 100 °C. The reaction was diluted with EtOAc (10 mL) and washed with satd NaHCO₃ (2 x 10 mL) and brine (10 mL). The organic layer was dried (Na₂SO₄) and concentrated and the residue was purified by RP-HPLC (C18), eluting with 40-70% CH₃CN in 0.1% TFA/H₂O over 10 min to give 0.021 g (34 %) the title compound. ¹H-NMR (400 MHz, CD₃OD): δ 8.84 (d, 2H), 8.59 (d, 1H), 8.42 (d, 2H), 7.94 (d, 1H), 7.86 (dd, 1H), 7.56 (d, 1H), 7.44 (d, 1H), 3.12 (m, 2H), 2.96. (m, 2H), 1.96 (m, 2H), 1.60 (m, 3H), 1.14 (d, 3H). Mass spectrum (ESI, m/z): Calcd. for C₂₃H₂₂N₄O₂, 387.2 (M+H), found 387.2.

Example 14

3H-Imidazole-4-carboxylic acid (2-piperidin-1-yl-phenyl)-amide bis(trifluoroacetic acid salt).




a) 1-(2-Trimethylsilyl-ethoxymethyl)-1H-imidazole-4-carboxyate sodium salt



A flask charged with 1H-imidazole-4-carboxylic acid methyl ester (0.29 g, 2.3 mmol), K₂CO₃ (0.60 g, 4.3 mmol), SEM-Cl (0.45 mL, 2.5 mmol) and DMF (5 mL) was heated for 12 h at 80 °C. The reaction was diluted with EtOAc (20 mL) and washed with water (20 mL) and brine (20 mL) and the organic layer dried over MgSO₄ and concentrated. The residue was purified by elution from a 20-g SPE cartridge (silica) with 5% MeOH/DCM to give 0.50 g (85%) of 1-(2-trimethylsilyl-ethoxymethyl)-1H-imidazole-4-carboxylic acid methyl ester. This compound was stirred overnight at RT in MeOH (3.0 mL) and 1N NaOH (1.9 mL) and then concentrated to give 0.43 g (70%) of the title compound as a white solid. Mass spectrum (ESI), m/z: Calcd. for C₁₀H₁₈N₂O₃Si, 243.1 (M+H), found 243.1.

b) 1-(2-Trimethylsilyl-ethoxymethyl)-1H-imidazole-4-carboxylic acid (2-piperidin-1-yl-phenyl)-amide



A flask was charged with 1-(2-trimethylsilyl-ethoxymethyl)-1H-imidazole-4-carboxylate sodium salt (70 mg, 0.26 mmol) (as prepared in the previous step), 2-piperidin-1-yl-phenylamine (36 mg, 0.20 mmol), EDCI (60 g, 0.31 mmol), DMAP (25 mg, 0.20 mmol), and DMF (1 mL) and stirred for 3 h at RT. The reaction was diluted with EtOAc (10 mL) and washed with brine (2 x 10 mL), and the organic layer was dried over Na₂SO₄ and then


concentrated. The title compound was eluted from a 5-g SPE cartridge (silica) with 30 % EtOAc/hexane to give 80 mg (97 %) of a white solid. Mass spectrum (ESI, m/z): Calcd. for $C_{21}H_{32}N_4O_2Si$, 401.2 (M+H), found 401.1.

c) 3H-Imidazole-4-carboxylic acid (2-piperidin-1-yl-phenyl)-amide bis(trifluoroacetic acid salt).


To a solution of 1-(2-trimethylsilyl-ethoxymethyl)-1H-imidazole-4-carboxylic acid (2-piperidin-1-yl-phenyl)-amide (80 mg, 0.20 mmol) (as prepared in the previous step) in EtOH (0.6 mL) was added 6N HCl (0.3 mL) and the mixture heated to 75 °C for 6 h. The mixture was concentrated and the title compound was purified by RP-HPLC (C18) eluting with 5-30% CH_3CN in 0.1% TFA/ H_2O over 10 min to give 35 mg (35%) of a white solid. ^1H -NMR (400 MHz, $DMSO-d_6$): δ 10.00 (s, 1H), 8.28 (m, 1H), 8.16 (m, 1H), 7.98 (s, 1H), 7.22 (m, 1H), 7.10 (m, 2H), 2.84 (m, 4H), 1.80 (m, 4H), 1.58 (m, 2H). Mass spectrum (ESI, m/z): Calcd. for $C_{15}H_{18}N_4O$, 271.2 (M+H), found 271.2.

Example 15

5-Cyano-1H-imidazole-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide trifluoroacetic acid salt




a) 1-(2-Trimethylsilyl-ethoxymethyl)-1H-imidazole-4-carbonitrile



A flask charged with imidazole-4-carbonitrile (0.50 g, 5.2 mmol) (Synthesis, 677 (2003)) 2-(trimethylsilyl)ethoxymethyl chloride (SEMCl) (0.95 mL, 5.3 mmol), K_2CO_3 (1.40 g, 10.4 mmol), and acetone (5 mL) was stirred for 10 h at RT. The mixture was diluted with EtOAc (20 mL) and washed with water (20 mL) and brine (20 mL) and the organic layer dried over $MgSO_4$.


The crude product was eluted from a 20-g SPE cartridge (silica) with 30 % EtOAc/hexane to give 0.80 g (70 %) of the title compound as a colorless oil. Mass spectrum (CI (CH₄), m/z) Calcd. for C₁₀H₁₇N₃OSi, 224.1 (M+H), found 224.1.

b) 2-Bromo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-4-carbonitrile



To a solution of 1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-4-carbonitrile (0.70 g, 3.1 mmol) (as prepared in the previous step) in CCl₄ (10 mL) was added NBS (0.61 g, 3.4 mmol) and AIBN (2 mg, catalytic), and the mixture heated at 60 °C for 4 h. The reaction was diluted with EtOAc (30 mL) and washed with NaHCO₃ (2 x 30 mL) and brine (30 mL) and the organic layer was dried over Na₂SO₄ and then concentrated. The title compound was eluted from a 20-g SPE cartridge (silica) with 30 % EtOAc/hexane to give 0.73 g (77 %) of a yellow solid. Mass spectrum (CI (CH₄), m/z) Calcd. for C₁₀H₁₆BrN₃OSi, 302.0/304.0 (M+H), found 302.1/304.1.

c) 4-Cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid ethyl ester



To a solution of 2-bromo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-4-carbonitrile (0.55 g, 1.8 mmol) (as prepared in the previous step) in THF (6 mL) at -40 °C was added dropwise a solution of 2M i-PrMgCl in THF (1 mL). The reaction was allowed to stir for 10 min at -40 °C and then cooled to -78 °C, and ethyl cyanoformate (0.3 g, 3.0 mmol) was added. The reaction allowed to attain RT and stirred for 1 h. The reaction was quenched with satd aq NH₄Cl, diluted with EtOAc (20 mL) and washed with brine (2 x 20 mL), and the organic layer was dried over Na₂SO₄ and then concentrated. The title compound was eluted from a 20-g SPE cartridge (silica) with 30 % EtOAc/hexane to give 0.40 g (74 %) of a colorless oil. Mass spectrum (ESI, m/z): Calcd. for C₁₃H₂₁N₃O₃Si, 296.1 (M+H), found 296.1.

d) 4-Cyano-1-(2-trimethylsilyl-ethoxymethyl)-1H-imidazole-2-carboxylate potassium salt




To a solution of 4-cyano-1-(2-trimethylsilyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid ethyl ester (0.40 g, 1.3 mmol) (as prepared in the previous step) in ethanol (3 mL) was added a solution of 6M KOH (0.20 mL) and the reaction was stirred for 10 min and then concentrated to give 0.40 g (100 %) of the title compound as a yellow solid. ¹H-NMR (400 MHz, CD₃OD): δ 7.98 (s, 1H), 5.92 (s, 2H), 3.62 (m, 2H), 0.94 (m, 2H), 0.00 (s, 9H). Mass spectrum (ESI-neg, m/z) Calcd. for C₁₁H₁₇N₃O₃Si, 266.1 (M-H), found 266.0.

e) 5-Cyano-1H-imidazole-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide trifluoroacetic acid salt

The title compound was prepared by coupling 4-cyano-1-(2-trimethylsilyl-ethoxymethyl)-1H-imidazole-2-carboxylate potassium salt (as prepared in the previous step) and 2-piperidin-1-yl-phenylamine according to the procedure in Example 14, step (b) followed by SEM deprotection according to the procedure in Example 14, step (c). The title compound was purified by RP-HPLC (C18), eluting with 10-70% CH₃CN in 0.1% TFA/H₂O over 15 min. ¹H-NMR (400 MHz, CD₃OD): δ 8.38 (m, 1H), 8.06 (s, 1H), 7.32 (m, 1H), 7.18 (m, 2H), 2.92 (m, 4H), 1.92 (m, 4H), 1.72 (m, 2H). Mass spectrum (ESI, m/z): Calcd. for C₁₆H₁₇N₅O, 296.1 (M+H), found 296.1.

The claimed invention is:

1. A compound of Formula I:



or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein

A is

phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -COR_a, -CN, -C(NH)NH₂, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b; or

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with one or more of -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, sulfonamidoalkyl, guanidinoalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -COR_a, -CN, -C(NH)NH₂, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b;

R₁ is

-H, aryl, -COR_a, -COR_a, -COOR_a, -CONR_aR_b, -SO₂R_a or -SO₂NR_aR_b;

X is

-CO-, -C(=NH)-, -CS-, -CON(R_a)-, -CS(NR_a)-, -SO₂- or -CR_aR_b-;

R₂ and R₃ are independently

-H, -C₁₋₆ alkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, -COR_a, -COR_a, -COOR_a, -CONR_aR_b, -SO₂R_a or -SO₂NR_aR_b; or

R₂ and R₃, taken together with the attached nitrogen, form

a 5- to 7-membered heterocyclic or heteroaromatic ring containing from one to three heteroatoms selected from N, O or S, which may be optionally substituted with -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, -COR_a, -CN, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b; and

W is

phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C₁₋₄ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, halogen, hydroxy, -CF₃, alkoxy, aryloxy, arylalkoxy, -OCF₃, -COR_a, -CN, -C(NH)NH₂, -COOR_a, -CONR_aR_b, -NHCOR_aR_b, -NHSO₂R_a, -NO₂, -SOR_a, -SO₃R_a or -SO₂NR_aR_b; or

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heterocyclic or heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, -COR_a, -CN, -C(NH)NH₂, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b,

wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

2. A compound according to claim 1, wherein

A is phenyl;

R₁ is -H; and

R₂ and R₃, taken together with the attached nitrogen, form a piperidine, piperazine, morpholine, thiomorpholine, pyrrolidine, pyrroline, pyrazolidine, pyrazoline, imidazolidine or imidazoline ring which may be optionally substituted with -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, -COR_a, -CN, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b,

wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

3. A compound according to claim 2, wherein

W is a phenyl, furan, thiophene, isoxazole, pyrrole, oxazole, thiazole, imidazole, pyrazole, isothiazole, triazole, pyridine, pyridazine, pyrimidine, pyrazine or triazine ring which may be optionally substituted with -C₁₋₆ alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, halogen, hydroxy, -CF₃, alkoxy, aryl, aralkyl, heteroaralkyl, aryloxy, arylalkoxy, -OCF₃, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, -COR_a, -CN, -C(NH)NH₂, -COOR_a, -CONR_aR_b, -N(R_a)COR_b, -NO₂, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b,

wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, haloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

4. A compound of claim 1, which is one of
- 5-cyano-furan-2-carboxylic acid [2-(4-acetylamino-piperidin-1-yl)-phenyl]-amide,
 - 5-cyano-1H-pyrrole-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide,
 - 5-cyano-furan-2-carboxylic acid (4-methoxy-2-piperidin-1-yl-phenyl)-amide,
 - 5-cyano-furan-2-carboxylic acid (4-imidazol-1-yl-2-piperidin-1-yl-phenyl)-amide,
 - 5-cyano-furan-2-carboxylic acid (4-dimethylamino-2-piperidin-1-yl-phenyl)-amide,
 - 5-cyano-furan-2-carboxylic acid [2-(4,4-difluoro-piperidin-1-yl)-phenyl]-amide,
 - 5-cyano-furan-2-carboxylic acid (4-ethoxy-2-piperidin-1-yl-phenyl)-amide,
 - 5-cyano-furan-2-carboxylic acid (3-chloro-2-piperidin-1-yl-phenyl)-amide,
 - 5-cyano-furan-2-carboxylic acid (3-methyl-2-piperidin-1-yl-phenyl)-amide,
 - 5-cyano-furan-2-carboxylic acid (2-piperidin-1-yl-4-pyrazol-1-yl-phenyl)-amide,
 - 5-cyano-furan-2-carboxylic acid [4-(acetyl-methyl-amino)-2-piperidin-1-yl-phenyl]-amide,
 - 5-cyano-furan-2-carboxylic acid (4-acetylamino-2-piperidin-1-yl-phenyl)-amide,
 - 5-cyano-furan-2-carboxylic acid [2-(4-methyl-piperidin-1-yl)-4-pyridin-4-yl-phenyl]-amide bis(trifluoroacetic acid salt),
 - 3H-imidazole-4-carboxylic acid (2-piperidin-1-yl-phenyl)-amide bis(trifluoroacetic acid salt), or
 - 5-cyano-1H-imidazole-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide trifluoroacetic acid salt,
- and pharmaceutically acceptable salts thereof.
5. A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
6. A method for inhibiting protein tyrosine kinase activity, comprising contacting the kinase with an effective inhibitory amount of at least one compound of claim 1.
7. A method according to claim 11, wherein the protein tyrosine kinase is c-fms.
8. A method of treating inflammation in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 1.

9. A method of treating cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 1.
10. A method of treating cardiovascular disease in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 1.
11. A method of treating glomerulonephritis, rheumatoid arthritis, psoriasis, diabetes, tumor related angiogenesis, restenosis, schizophrenia or Alzheimer's dementia in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 1.
12. A pharmaceutical dosage form comprising a pharmaceutically acceptable carrier and from about 0.5 mg to about 10 g of at least one compound of claim 1.
13. A dosage form according to claim 12 adapted for parenteral or oral administration.